Drugs / PKN605
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07217067 | Oct 2025 → Sep 2027 expected | atrial fibrillation | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PKN605 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07217067 ↗ |
| Route | Oral | “PKN605 is an oral formulation” NCT07217067 ↗ |